Aggravation of L-DOPA-induced neurotoxicity by tetrahydropapaveroline in PC12 cells

Biochemical Pharmacology

Volumn 66, Issue 9, 2003, Pages 1787-1795

  Lee, Jae Joon ^a   Kim, Yu Mi ^a   Yin, Shou Yu ^a   Park, Hee Dong ^a   Kang, Min Hee ^a   Hong, Jin Tae ^a   Lee, Myung Koo ^a  

^a Chungbuk National University   (South Korea)

Author keywords

Apoptosis; L DOPA; Neurotoxicity; Oxidative stress; PC12 cells; Tetrahydropapaveroline

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; DRUG METABOLITE; LEVODOPA; REACTIVE OXYGEN METABOLITE; TETRAHYDROPAPAVEROLINE; TETRAZOLIUM BLUE;

ANIMAL CELL; APOPTOSIS; ARTICLE; BIOASSAY; CELL LOSS; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DISEASE EXACERBATION; FLOW CYTOMETRY; INCUBATION TIME; LONG TERM CARE; NEUROTOXICITY; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; RAT;

EID: 0141888290     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00421-0     Document Type: Article

References (41)

1. Nagatsu T. Isoquinoline neurotoxins in the brain and Parkinson's disease. Neurosci. Res. 29:1997;99-111.
2. Sandler M., Carter S.B., Hunter K.R., Stern G.M. Tetrahydroisoquinoline alkaloids: in vivo metabolites of L-DOPA in man. Nature. 241:1973;439-443.
3. Turner A.J., Baker K.M., Algeri S., Frigerio A., Garattini S. Tetrahydropapaveroline: formation in vivo and in vitro in rat brain. Life Sci. 14:1974;2247-2257.
4. Cashaw J.L. Tetrahydropapaveroline in brain regions of rats after acute ethanol administration. Alcohol. 10:1993;133-138.
5. Maruyama W., Sango K., Iwasa K., Minami C., Dostert P., Kawai M., Moriyasu M., Naoi M. Dopaminergic neurotoxins, 6,7-dihydroxy-1-(3′ ,4′-dihydroxybenzyl)-isoquinolines, cause different types of cell death in SH-SY5Y cells: apoptosis was induced by oxidized papaverolines and necrosis by reduced tetrahydropapaverolines. Neurosci. Lett. 291:2000;89-92.
6. Storch A., Ott S., Hwang Y.I., Ortmann R., Hein A., Frenzel S., Matsubara K., Ohta S., Wolf H.U., Schwarz J. Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson's disease: studies using heterologous expression systems of the dopamine transporter. Biochem. Pharmacol. 7112:2002;1-12.
7. Surh Y.J. Tetrahydropapaveroline, a dopamine-derived isoquinoline alkaloid, undergoes oxidation: implications for DNA damage and neuronal cell death. Eur. J. Clin. Invest. 29:1999;650-651.
8. Morikawa N., Nakagawa H.Y., Mizuno Y. Effect of dopamine, dimethoxyphenylethamine, papaverine, and related compounds on mitochondrial respiration and complex activity. J. Neurochem. 66:1996;1174-1181.
9. McNaught K.St.P., Carrupt P.A., Altmore C., Cellamare S., Carotti A., Testa B., Jenner P., Marsden C.D. Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease. Biochem. Pharmacol. 56:1998;921-933.
10. Greene L.A., Tischler A.S. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc. Natl. Acad. Sci. U.S.A. 73:1976;2424-2428.
11. Tischler A.S., Perlman R.L., Morse G.M., Sheard B.E. Glucocorticoids increase catecholamine synthesis and storage in PC12 pheochromocytoma cell culture. J. Neurochem. 40:1983;364-370.
12. +)-induced cell death in PC12 sells: inhibitory effects of several drugs. Neurochem. Int. 25:1994;419-424.
13. Marsden C.D. Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 57:1994;672-681.
14. Lloyd K.G., Davidson L., Hornykiewicz O. The neurochemistry of Parkinson's disease: effect of L-DOPA therapy. J. Pharmacol. Exp. Ther. 195:1975;453-464.
15. Hornykiewicz O. The mechanisms of action of L-DOPA in Parkinson's disease. Life Sci. 15:1994;1249-1259.
16. Marsden C.D., Parkes J.D. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet. 1:1976;292-296.
17. Marsden C.D., Parkes J.D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet. 1:1977;345-349.
18. Friedman A., Sienkiewicz J. Psychotic complications of long-term levodopa therapy in Parkinson's disease. Acta Neurol. Scand. 84:1991;111-113.
19. Ogawa N. Levodopa and dopamine agonists in the treatment of Parkinson's disease: advantages and disadvantages. Eur. J. Neurol. 34(Suppl. 3):1994;20-28.
20. Blunt S.B., Jenner P., Marsden C.D. Suppressive effect of L-DOPA on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov. Disord. 8:1993;129-137.
21. Walkinshaw G., Waters C.M. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. J. Clin. Invest. 95:1995;2458-2464.
22. Basma A.N., Morris E.J., Nicklas W.J., Geller H.M. L-DOPA cytotoxicity to PC12 cells in culture is via its autoxidation. J. Neurochem. 64:1995;825-832.
23. Migheli R., Godani C., Bciola L., Delodu M.R., Serra P.A., Zangani D., Natale G.D., Miele E., Desole M.S. Enhancing effect of manganese on L-DOPA-induced apoptosis in PC12 cells: role of oxidative stress. J. Neurochem. 73:1999;1155-1163.
24. Sandstrom P.A., Manhie M.D., Buttke T.H. Inhibition of activation-induced death in T cell hybridomas by thiol antioxidant: oxidative stress as a mediator of apoptosis. J. Neurocyte Biol. 55:1994;221-226.
25. Mosman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays. J. Immunol. Methods. 65:1983;55-63.
26. Gunasekar P.G., Kanthasamy A.G., Borowitz J.L., Isom G.E. NMDA receptor activation produces concurrent generation of reactive oxygen species: implication for cell death. J. Neurochem. 65:1995;2016-2021.
27. Ohta S. Isoquinolines in Parkinson's disease. In: Storch A, Collins MA, editors. Neurotoxic factors in Parkinson's disease and related disorders, vol. 3. New York: Plenum Press; 2000. p. 33-42.
28. McNaught K.St.P., Thull U., Carrupt P.A., Altmore C., Cellamare S., Carotti A., Teats B., Jenner P., Marsden C.D. Toxicity to PC12 cells of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurosci. Lett. 206:1996;37-40.
29. Bai J., Nakamura H., Hattori I., Tanito M., Yodoi J. Thioredoxin suppresses 1-methyl-4-phenylpyridinium-induced neurotoxicity in rat PC12 cells. Neurosci. Lett. 321:2002;81-84.
30. Langston J.W., Irwin I. MPTP: current concepts and controversies. Clin. Neuropharmacol. 9:1986;485-507.
31. Seyfried J., Soldner F., Jung W.S., Schulz J.B., Klockgether T., Kovar K.A., Wullner U. Effect of 1-methyl-4-phenylpyridinium on glutathione in rat pheochromocytoma PC12 cells. Neurochem. Int. 35:2000;489-497.
32. Rossor M.N., Watkins J., Brown M.J., Reid J.L., Dollery C.T. Plasma levodopa dopamine and therapeutic response following levodopa therapy of Parkinsonian patients. Brain Res. 46:1980;385-392.
33. Rosenberg P.A. Catecholamine toxicity in cerebral cortex in dissociated cell culture. J. Neurosci. 8:1988;2887-2894.
34. Walkinshaw G., Waters C.M. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. J. Clin. Invest. 95:1995;2458-2464.
35. Smith T.S., Parker W.D., Bennett J.P. L-DOPA increases nigral production of hydroxyl radicals in vivo: potential L-DOPA toxicity? Neuroreport. 5:1994;1009-1011.
36. Vermes I., Haanen C. Apoptosis and programmed cell death in health and disease. Adv. Clin. Chem. 31:1994;177-246.
37. Seaton T.A., Cooper J.M., Schapira A.H.V. Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex inhibitors. Brain Res. 777:1997;110-118.
38. McNaught K.St.P., Thull U., Carrupt P.A., Altmore C., Cellamare S., Carotti A., Testa B., Jenner P., Marsden C.D. Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem. Pharmacol. 50:1995;1903-1911.
39. McNaught K.St.P., Altmore C., Cellamare S., Carotti A., Thull U., Carrupt P.A., Testa B., Jenner P., Marsden C.D. Inhibition of α-ketoglutarate dehydrogenase by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuroreport. 6:1995;1105-1108.
40. McNaught K.St.P., Thull U., Carrupt P.A., Altmore C., Cellamare S., Carotti A., Testa B., Jenner P., Marsden C.D. Effects of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP) on mitochondrial respiration. Biochem. Pharmacol. 51:1996;1503-1511.
41. Morikawa N., Naoi N., Maruyama W., Ohta S., Kotake Y., Kawai H., Niwa T., Dostert P., Mizuno Y. Effects of various tetrahydroisoquinoline derivatives on mitochondrial respiration and electron transfer complexes. J. Neural. Trans. 105:1998;677-688.